McNeil Consumer Healthcare recalls lots of infants’, children’s OTC medicines
FORT WASHINGTON, Pa. McNeil Consumer Healthcare on Friday voluntarily recalled all lots that have not yet expired of certain over-the-counter children’s and infants’ liquid products in consultation with the Food and Drug Administration.
McNeil Consumer initiated the recall because some of these products may not meet required quality standards, though no adverse medical events have been reported, the company stated. “However, as a precautionary measure, parents and caregivers should not administer these products to their children.”
Some of the products included in the recall may contain a higher concentration of active ingredient than is specified; others may contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles.
“While the potential for serious medical events is remote, the company advises consumers who have purchased these recalled products to discontinue use,” McNeil stated.
The company is conducting a comprehensive quality assessment across its manufacturing operations and has identified corrective actions that will be implemented before new manufacturing is initiated at the plant where the recalled products were made.
For a full list of products recalled, visit http://www.mcneilproductrecall.com/page.jhtml?id=/include/new_recall.inc
Everlast ProLine seeks to maximize workout benefits for athletes
NEW YORK Everlast Sports Nutrition is launching a collection of nutrition products specifically created for the dedicated athlete, called Everlast ProLine.
The collection features advanced nutrients, including natural sweeteners and natural flavors, and includes products that maximize workout benefits while managing weight and recovery.
Developed by a team of industry professionals that includes nutritionists, athletes and fitness-enthusiasts, the ProLine was created to deliver scientifically validated ingredients in proven sports nutrition products for optimum athletic performance. Formulas were carefully chosen, tested and combined to support optimal strength, energy and focus.
Everlast Sports Nutrition ProLine will begin shipping in May.
Study: Vitamin B may decrease kidney function in diabetic nephropathy patients
NEW YORK Patients with a kidney disease caused by diabetes that receive high-dose vitamin B therapy are more likely to have decreased kidney function and an increased risk of heart attack and stroke, a new study found.
Published in the Apr. 28 issue of the Journal of the American Medical Association, Andrew House, M.D., of the University of Western Ontario, and J. David Spence, M.D., of the Robarts Research Institute, London, Ontario, and colleagues conducted a study to examine whether B-vitamin therapy would slow the progression of diabetic nephropathy and prevent vascular events in 238 patients with Type 1 or 2 diabetes. Data taken from patients in the randomized, placebo-controlled trial between May 2001 and May 2007 found the measure of kidney function — radionuclide glomerular filtration rate, or GFR — rapidly decreased in those who consumed vitamin B6 and B12, between baseline and 36 months, compared with the placebo group. Additionally, the researchers found that risk of such cardiovascular events as heart attack, stroke, revascularization, and all-cause mortality, doubled in the B-vitamin group.
Meanwhile, House, Spence and colleagues also added that they tested the patients’ levels of homocysteine, a naturally occurring amino acid found in blood plasma. While high levels of homocysteine are more likely to cause heart attack and other diseases, the researchers noted that participants in the B-vitamin group had an average decrease while participants in the placebo group had an average increase. This result, the authors concluded, should not necessarily be a guide for those interested in testing this theory outside of a clinical trial.
"Given the recent large-scale clinical trials showing no treatment benefit, and our trial demonstrating harm, it would be prudent to discourage the use of high-dose B vitamins as a homocysteine-lowering strategy outside the framework of properly conducted clinical research," the authors concluded.